검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Ebglyss (lebrikizumab) | Dupixent (dupilumab) | Cyclosporine | Azathioprine | Ruxolitinib |
Overview Company | Eli Lilly | Sanofi / Regeneron | Novartis | GlaxoSmithKline | Incyte Corporation |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-13 | IL-4Rα | FRα | ANCA Associated Vasculitis (AAV) | FRα |
Overview Indication | Atopic dermatitis | Atopic dermatitis, asthma, CRSwNP, EoE | Psoriasis; Atopic Dermatitis | Psoriasis; Atopic Dermatitis | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | ACTIVE | RECRUITING | DISCONTINUED |
MoA Mechanism | Anti-IL-13 monoclonal antibody | targeting specific inflammatory pathway | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling | — | targeting the interferon-gamma pathway |
MoA Biomarker | EASI, IGA | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat | biomarker discovery for thiopurine response in Crohn disease: Plasma histidine as a promising biomarker | biomarkers, increased lipopolysaccharide (LPS) levels, and diamine oxidase (DAO), along with histopathologica |
PK/PD Half-life | 24.5 h | — | — | 5 h | — |
PK/PD Species | Mouse | — | Mouse, carbamazepine, cyclosporine, and quinidine. | Mouse, Rat | Mouse, Rat |
PK/PD Animal (cat.) | Mouse | In vitro | Mouse | Mouse, Rat | Mouse, Rat, In vitro |
PK/PD Experiment | pharmacokinetic | PD | pharmacokinetic | PK | PD |
Toxicology Species | Cynomolgus monkey, Mouse | Mouse | Mouse, Rat, Hamster, carbamazepine, cyclosporine, and quinidine. | Mouse, Rat, Rabbit, Human | Mouse, Rat |
Toxicology Animal (cat.) | NHP | Mouse | Mouse, Rat | Human, Mouse | Mouse, Rat |
Toxicology Major finding | — | — | — | Hepatotoxicity manifest by elevation of serum alkaline phosphatase, bilirubin, and/or serum | Thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia have occurred |
Clinical Primary efficacy | ORR 75% | ORR 0.45% | ORR 35% | — | ORR 54.5% |
Clinical ORR | EASI-75 ~59% (ADvocate) | -0.45 | 35% | — | 54.5% |
Clinical Result source | ADvocate | ClinicalTrials.gov NCT02912468 | ClinicalTrials.gov NCT00104858 | — | ClinicalTrials.gov NCT03112603 |
Clinical Data Tier / Score | S · 91 | A · 65 | B · 51 | C · 42 | C · 40 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Ebglyss (lebrikizumab) | Dupixent (dupilumab) | Cyclosporine | Azathioprine | Ruxolitinib |
Overview Company | Eli Lilly | Sanofi / Regeneron | Novartis | GlaxoSmithKline | Incyte Corporation |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-13 | IL-4Rα | FRα | ANCA Associated Vasculitis (AAV) | FRα |
Overview Indication | Atopic dermatitis | Atopic dermatitis, asthma, CRSwNP, EoE | Psoriasis; Atopic Dermatitis | Psoriasis; Atopic Dermatitis | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | ACTIVE | RECRUITING | DISCONTINUED |
MoA Mechanism | Anti-IL-13 monoclonal antibody | targeting specific inflammatory pathway | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling | — | targeting the interferon-gamma pathway |
MoA Biomarker | EASI, IGA | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat | biomarker discovery for thiopurine response in Crohn disease: Plasma histidine as a promising biomarker | biomarkers, increased lipopolysaccharide (LPS) levels, and diamine oxidase (DAO), along with histopathologica |
PK/PD Half-life | 24.5 h | — | — | 5 h | — |
PK/PD Species | Mouse | — | Mouse, carbamazepine, cyclosporine, and quinidine. | Mouse, Rat | Mouse, Rat |
PK/PD Animal (cat.) | Mouse | In vitro | Mouse | Mouse, Rat | Mouse, Rat, In vitro |
PK/PD Experiment | pharmacokinetic | PD | pharmacokinetic | PK | PD |
Toxicology Species | Cynomolgus monkey, Mouse | Mouse | Mouse, Rat, Hamster, carbamazepine, cyclosporine, and quinidine. | Mouse, Rat, Rabbit, Human | Mouse, Rat |
Toxicology Animal (cat.) | NHP | Mouse | Mouse, Rat | Human, Mouse | Mouse, Rat |
Toxicology Major finding | — | — | — | Hepatotoxicity manifest by elevation of serum alkaline phosphatase, bilirubin, and/or serum | Thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia have occurred |
Clinical Primary efficacy | ORR 75% | ORR 0.45% | ORR 35% | — | ORR 54.5% |
Clinical ORR | EASI-75 ~59% (ADvocate) | -0.45 | 35% | — | 54.5% |
Clinical Result source | ADvocate | ClinicalTrials.gov NCT02912468 | ClinicalTrials.gov NCT00104858 | — | ClinicalTrials.gov NCT03112603 |
Clinical Data Tier / Score | S · 91 | A · 65 | B · 51 | C · 42 | C · 40 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교